1. Home
  2. AQB vs ARTL Comparison

AQB vs ARTL Comparison

Compare AQB & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AquaBounty Technologies Inc.

AQB

AquaBounty Technologies Inc.

N/A

Current Price

$0.93

Market Cap

3.7M

Sector

N/A

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$5.40

Market Cap

3.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AQB
ARTL
Founded
1991
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
AQB
ARTL
Price
$0.93
$5.40
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
24.9K
2.5M
Earning Date
03-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,472,659.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.85
52 Week High
$2.95
$28.60

Technical Indicators

Market Signals
Indicator
AQB
ARTL
Relative Strength Index (RSI) 49.32 60.96
Support Level $0.86 $3.68
Resistance Level $0.97 $6.75
Average True Range (ATR) 0.07 1.10
MACD -0.00 0.39
Stochastic Oscillator 46.42 49.89

Price Performance

Historical Comparison
AQB
ARTL

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: